electroCore, Inc. (NASDAQ:ECOR) is expected to report third quarter earnings results, after market close, on Thursday 12th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.14 per share.
Looking ahead, the full year loss are expected at $ 0.64 per share on the revenues of $ 3.49 million.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 1.00 million ~ $ 1.00 million
Full Year 2020 topline are forecasted in a range of$ 7.00 million ~ $ 9.00 million
Click Here For More Historical Outlooks Of electroCore, Inc.
Previous Quarter Performance
electroCore, Inc. disclosed loss for the second quarter of $ 0.13 per share, from the revenue of $ 0.75 million. The quarterly revenues gained 20.97 percent compared with the same quarter last year. Street analysts expected electroCore, Inc. to report loss of $ 0.21 per share on revenue of $ 0.86 million for the second quarter. The bottom line results beat street analysts by $ 0.08 or 38.10 percent, at the same time, top line results fell short of analysts by $ 0.11 million or 12.79 percent.
Stock Performance
Shares of electroCore, Inc. traded up $ 0.14 or 8.86 percent on Wednesday, reaching $ 1.72 with volume of 448.80 thousand shares. electroCore, Inc. has traded high as $ 1.75 and has cracked $ 1.59 on the downward trend
The closing price of $ 1.72, representing a 393.75 % increase from the 52 week low of $ 0.32 and a 52.12 % decrease over the 52 week high of $ 3.30.
The company has a market capital of $ 76.58 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Recent Analyst recommendations
- On 30th September 2020, initiated by Maxim Group at Buy rating, with $ 3.00 target price.
Conference Call
electroCore, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 877-407-4018 U.S. or 201-689-8471 Toll Number, with passcode : 13711577 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.electrocore.com
electroCore, Inc., a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve (VNS) stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. The company is developing gammaCore, a prescription-only non-invasive VNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, which is a handheld delivery system for multi-year use prescribed on a monthly basis.
